Wells Fargo & Company Forecasts Strong Price Appreciation for Crescent Capital BDC (NASDAQ:CCAP) Stock

Crescent Capital BDC (NASDAQ:CCAP) had its price objective hoisted by equities research analysts at Wells Fargo & Company from $18.00 to $19.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential downside of 2.71% from the company’s current price.

Separately, Keefe, Bruyette & Woods increased their price objective on Crescent Capital BDC from $19.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, November 25th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $19.33.

Crescent Capital BDC Stock Performance

Crescent Capital BDC stock opened at $19.53 on Wednesday. Crescent Capital BDC has a fifty-two week low of $15.91 and a fifty-two week high of $20.03. The firm’s 50 day simple moving average is $19.38 and its 200-day simple moving average is $18.77. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.26 and a quick ratio of 1.26. The company has a market cap of $723.82 million, a P/E ratio of 7.66 and a beta of 0.81.

Crescent Capital BDC (NASDAQ:CCAP) last announced its earnings results on Tuesday, November 12th. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.07. The company had revenue of $51.63 million for the quarter, compared to the consensus estimate of $48.76 million. Crescent Capital BDC had a net margin of 47.06% and a return on equity of 12.20%. During the same period in the previous year, the business earned $0.59 EPS. As a group, equities research analysts predict that Crescent Capital BDC will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Crescent Capital BDC

A number of large investors have recently added to or reduced their stakes in CCAP. Montag A & Associates Inc. acquired a new stake in shares of Crescent Capital BDC in the fourth quarter valued at about $35,000. Van ECK Associates Corp increased its position in Crescent Capital BDC by 2.3% in the 4th quarter. Van ECK Associates Corp now owns 45,562 shares of the company’s stock worth $876,000 after buying an additional 1,006 shares during the period. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Crescent Capital BDC by 11.9% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 105,343 shares of the company’s stock worth $2,025,000 after buying an additional 11,161 shares during the last quarter. Redhawk Wealth Advisors Inc. bought a new stake in shares of Crescent Capital BDC in the fourth quarter valued at approximately $659,000. Finally, Confluence Investment Management LLC increased its stake in Crescent Capital BDC by 0.9% during the fourth quarter. Confluence Investment Management LLC now owns 73,839 shares of the company’s stock valued at $1,419,000 after acquiring an additional 633 shares during the period. Institutional investors own 49.46% of the company’s stock.

Crescent Capital BDC Company Profile

Crescent Capital BDC, Inc is as a business development company private equity / buyouts and loan fund. It specializes in directly investing. It specializes in middle market. The fund seeks to invest in United States.